RxDoctor Payments Data

Lauren Lyles, MD

Family Medicine · Richmond, VANPI 1689179145

Payments from drug & device makers

$3,520in general payments, 2019–2025

Across 205 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$567
  • Lilly USA, LLC$406
  • Pfizer$394
  • AstraZeneca$358
  • Novo Nordisk$344
  • Amgen$208
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,508100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,520 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$11,588
Medicare patients
92
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,726
Breo ElliptaFluticasone/Vilanterol14$6,470
SynthroidLevothyroxine Sodium22$2,068
Atorvastatin Calcium119$984
Rosuvastatin Calcium53$725
Levothyroxine Sodium70$702
Albuterol Sulfate HfaAlbuterol Sulfate24$624
Montelukast Sodium34$483
Pantoprazole Sodium39$451
Losartan Potassium61$430
Fluoxetine Hcl28$408
Amlodipine Besylate77$380
Metformin Hcl ErMetformin Hcl30$302
Escitalopram Oxalate18$299
Famotidine31$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$46$16,19525 claims
AbbVieSynthroid$567$2,06822 claims
Upsher-smith Laboratories LLCTopiramate$85$2811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →